UK ITP Treatment Update: Quentin Hill on Generic Eltrombopag Access and Guidance
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, has shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag.
Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licensed treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar, and greater use of generic eltrombopag will result in a substantial, multi-million-pound cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP.
However, patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
You can find more information here.
Find more posts on Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25